Authors:
Monali Tayade, Shishanka Wangnoo
Download free PDF
Antiparasitic Drugs Market Size & Share 2026-2035
Report ID: GMI8043
|
Published Date: September 2026
|
Report Format: PDF/Excel/Dashboard/Platform
Download Free PDF
Explore Our Licensing Options:
Download Free PDF
Antiparasitic Drugs Market
Get a free sample of this report
What are you hoping to find?
Your PDF is on its way. Tell us little about your research goal, and we'll help you find the most relevant market insights.
Antiparasitic Drugs Market Size
The global antiparasitic drugs market was valued at USD 20.7 billion in 2025 and is projected to increase from USD 21.7 billion in 2026 to USD 36.2 billion by 2035, reflecting a 5.8% CAGR. Historical growth was 4.8%, with market value increasing from USD 17.9 billion in 2022 to USD 19.7 billion in 2024.
Antiparasitic Drugs Market Key Takeaways
Market Leader: GlaxoSmithKline led with over 12% market share in 2025.
Leading Players: Top 5 players in this market include GlaxoSmithKline, Novartis, Dr. Reddy’s Pharmaceuticals, Sanofi, Cipla, which collectively held a market share of 45% in 2025.
Antiparasitic drugs treat infections caused by protozoa, helminths, and ectoparasites. Their demand base spans high-volume preventive treatment programs, acute care for severe infections, and prescription-led management of imported or endemic disease. The market therefore combines low-cost, high-volume generic products with specialized formulations used in hospital and travel-medicine settings.
The underlying treatment need remains extensive. WHO reported an estimated 282 million malaria cases and 610,000 malaria deaths in 2024, with the WHO African Region accounting for 95% of malaria deaths. [1]World Health Organization - Malaria fact sheet, December 2024 - who.int Soil-transmitted helminth infections affect about 1.5 billion people globally, creating a large recurring need for medicines such as albendazole, mebendazole, ivermectin, and praziquantel. [2]World Health Organization - Soil-transmitted helminth infections fact sheet, January 2023 - who.int WHO also identified strongyloidiasis as a priority for expanded preventive chemotherapy, particularly in endemic settings with material prevalence among school-age children.
Public-health treatment programs are important to the market because they convert epidemiological burden into structured, recurring procurement. In 2023, approximately 1.495 billion people required interventions against neglected tropical diseases, despite a substantial reduction from the 2010 baseline. Malaria, helminthic disease, leishmaniasis, trypanosomiasis, and ectoparasitic infections also create differentiated demand for oral, injectable, and topical products rather than a single therapeutic format.
GMI Analyst View
We estimate that the market's expansion is supported less by a uniform increase in prescribing than by the persistence of several distinct purchasing systems: government-funded mass drug administration, hospital treatment for severe disease, and commercial dispensing for endemic, travel-related, and imported infections. The projected rise from USD 21.7 billion in 2026 to USD 36.2 billion in 2035 reflects this diversified demand base.
The clinical burden remains concentrated in lower-income endemic settings, while a meaningful share of market value is generated in countries with stronger diagnostic capacity, regulated pharmacy channels, and higher spending per treated case. WHO's 2024 malaria burden and the continuing scale of soil-transmitted helminth infection indicate that volume demand will remain anchored in antiprotozoal and anthelmintic therapies,. The commercial implication is that suppliers need both tender-scale manufacturing economics and the regulatory capability to serve higher-value specialty and hospital channels.
Key Drivers
Rising prevalence of parasitic infections
Parasitic disease prevalence remains the principal volume driver because treatment demand covers several pathogen classes and care settings. WHO recorded 282 million malaria cases in 2024, while soil-transmitted helminths continue to affect approximately 1.5 billion people,. This burden sustains demand for antimalarial combinations, deworming products, antiamoebic therapies, and medicines used in institutional prevention programs.
Disease control is also complicated by diagnostic and therapeutic challenges. WHO reported HRP2/HRP3-deleted *Plasmodium falciparum* parasites in 42 endemic countries during 2024, which can reduce the reliability of some rapid diagnostic tests. Such diagnostic gaps can delay targeted treatment and increase the importance of surveillance, confirmatory testing, and dependable access to appropriate antimalarials.
Increasing government initiatives and funding
Government and donor programs create predictable purchase cycles for essential antiparasitic medicines. The U.S. President's Malaria Initiative has invested approximately USD 10 billion since 2006 and received USD 795 million in FY2024 appropriations for activities across partner countries in Africa and Southeast Asia. [3]USAID Office of Inspector General - President's Malaria Initiative information, 2024 - oig.usaid.gov These programs support medicines, surveillance, therapeutic-efficacy monitoring, and supply systems, creating procurement demand that differs from conventional retail pharmaceutical purchasing.
Medicine-donation and mass-administration programs provide another source of recurring volume. WHO reported that more than 27.7 billion tablets and vials for neglected tropical diseases were delivered between 2011 and 2023, including approximately 2.1 billion in 2023. [4]World Health Organization - Announcing new initiatives to maximize efficiencies of medicine donation programmes for neglected tropical diseases, March 4, 2024 - who.int WHO's 2024 strongyloidiasis guideline further recommends annual ivermectin mass drug administration in qualifying endemic settings, expanding the potential institutional pathway for anthelmintic procurement.
Increasing global travel and migration
International movement broadens antiparasitic demand beyond endemic regions. CDC surveillance identified increased imported malaria cases in several U.S. southern border jurisdictions in association with migration through malaria-endemic countries. European surveillance similarly documented more than 34,000 imported malaria cases across reporting countries during 2015–2019.
Imported infections create demand for products that may be less routinely stocked in non-endemic markets, including intravenous artesunate, liposomal amphotericin B, and specialized therapies for leishmaniasis. This supports hospital and specialty-pharmacy demand, particularly where tropical medicine services, diagnostic laboratories, and travel-health providers are established.
Growing awareness and early diagnosis of parasitic diseases
Expanded surveillance, community outreach, and diagnostic capacity increase the proportion of infections that are identified and treated. WHO reported that more than 860 million people received treatment for neglected tropical diseases in 2023 through mass drug administration or individual case management. The treatment scale indicates the operational importance of local health-worker networks, school-based delivery, and dependable medicine availability.
Earlier detection can change the product mix as well as treatment volume. Confirmed cases are more likely to be directed toward pathogen-appropriate therapies, while improved adherence to malaria rapid diagnostic test results can reduce indiscriminate antimalarial use. Procurement systems therefore increasingly require reliable supply planning rather than only large aggregate medicine volumes.
Key Restraints
Increasing drug resistance
Drug resistance limits the durability of established treatment regimens and increases development, surveillance, and procurement complexity. Artemisinin partial resistance has been identified in *P. falciparum* isolates from Ethiopia, alongside parasites with HRP2/HRP3 deletions that can evade standard rapid diagnostic tests. The combination of reduced treatment sensitivity and diagnostic limitations raises the operational risk of delayed recognition of treatment failure.
Resistance concerns extend beyond malaria. Evidence from a One Health review indicates resistance across major anthelmintic classes in animal populations, including benzimidazoles, macrocyclic lactones, and levamisole. For manufacturers and public-health buyers, the constraint is not simply lower demand; it is a requirement to maintain therapeutic-efficacy monitoring, diversify supply, and support regimens that remain clinically appropriate in local settings.
Limited availability of novel drug pipelines
The pipeline for several parasitic diseases remains limited relative to resistance risk and unmet clinical need. A review of antiparasitic natural-product development highlighted attrition, supply constraints, intellectual-property barriers, and formulation challenges that impede translation into viable treatments. Pipeline scarcity is particularly material for kinetoplastid diseases, where commercial returns may not support conventional research investment.
Low purchasing power in many high-burden countries makes public-private development models important. Partnerships involving organizations such as Medicines for Malaria Venture and the Drugs for Neglected Diseases initiative have advanced products, but they do not eliminate the funding gap across all indications. This creates a market in which mature generic therapies remain commercially important even as resistance increases the need for innovation.
GMI Analyst View
Our analysis indicates that the market's primary structural tension is between expanding treatment need and the declining reliability of some established therapies. Public-health programs can sustain large medicine volumes, but they also expose suppliers to tender pricing, country-level registration requirements, and periodic shifts in treatment protocols. The resulting opportunity favors companies able to combine low-cost production with evidence of quality, regulatory compliance, and supply reliability.
Resistance changes the economics of innovation. It can create demand for new regimens and formulations, yet the affected populations often offer limited conventional commercial returns. WHO's strongyloidiasis guidance and malaria-control funding commitments support recurring procurement,, while evidence of artemisinin partial resistance emphasizes the need for replacement options. The forecast growth profile therefore depends on whether public procurement, philanthropy, and commercial specialty markets can collectively sustain both essential generic supply and development of differentiated therapies.
Antiparasitic Drugs Market Segment Analysis
By Drug Type
Anthelmintics
Anthelmintics held the largest market share at 50.21% in 2025 and are projected to grow at a 6.7% CAGR, reaching USD 18 billion by 2035. Their scale reflects broad use against soil-transmitted helminths, schistosomiasis, lymphatic filariasis, strongyloidiasis, and other worm infections. High-volume medicines such as albendazole, mebendazole, ivermectin, and praziquantel are central to preventive chemotherapy and routine treatment.
WHO's strongyloidiasis guidance strengthens the institutional case for ivermectin procurement where prevalence thresholds are met. The segment's commercial profile is shaped by repeat treatment cycles, large tender volumes, and price-sensitive generic competition rather than reliance on a small number of premium products.
Antiprotozoal
Antiprotozoal drugs accounted for 21.75% of market revenue in 2025 and are projected to record the fastest drug-type CAGR at 7.23%. The segment includes antimalarials and products used for leishmaniasis, giardiasis, trypanosomiasis, and amoebic disease. Malaria remains its largest epidemiological foundation, with 282 million cases reported globally in 2024.
Growth is supported by the need to protect efficacy against resistant malaria and to improve access to therapies for complex protozoal diseases. Novartis reported positive Phase III results for ganaplacide/lumefantrine solid dispersion formulation in November 2025, representing a potential alternative treatment approach for uncomplicated malaria. Product innovation is particularly relevant in this segment because resistance can shift demand toward combination regimens, simplified dosing, and treatments tailored to pediatric populations.
Ectoparasiticides
Ectoparasiticides represented 15.44% of market revenue in 2025 and are forecast to grow at a 6.81% CAGR. The segment includes therapies for scabies, lice, and other ectoparasitic infestations, delivered primarily through topical and oral formulations. Demand spans community treatment, household-level retail purchases, and public-health interventions in crowded settings.
Scabies management supports a distinct combination of retail and institutional demand because topical products can be self-administered while severe or widespread outbreaks may require coordinated treatment measures. The segment benefits from the growing use of formulations intended to limit systemic exposure while maintaining local therapeutic activity.
Other Drug Types
Other drug types accounted for 12.60% of market revenue in 2025 and are projected to grow at a 6.25% CAGR. This category includes specialized products that do not fit the core anthelmintic, antiprotozoal, or ectoparasiticide classifications. Agents with activity against multiple intestinal parasites can be valuable in clinical settings where diagnostic certainty is limited or co-infections are possible.
By Route of Administration
Oral
Oral products held the largest route-of-administration share at 54.10% in 2025, equivalent to USD 11.2 billion, and are projected to grow at a 7.41% CAGR. Tablets, dispersible products, capsules, and suspensions are compatible with mass drug administration, outpatient prescribing, and retail dispensing. Their logistical advantages are especially significant in programs that must reach schools, rural communities, and decentralized primary-care settings.
Pediatric suitability remains important for oral product development. WHO's neglected tropical disease roadmap identifies the need for age-appropriate formulations, including pediatric products for schistosomiasis treatment. Oral innovation can therefore improve both adherence and eligibility for population-based programs.
Injectable
Injectables represented 31.55% of market revenue in 2025 and are projected to grow at a 6.56% CAGR. The segment serves severe malaria, visceral leishmaniasis, advanced trypanosomiasis, and other cases requiring supervised administration. Its revenue contribution is closely linked to hospital infrastructure, specialist clinical pathways, and centralized procurement.
Injectables are less suited to high-volume preventive campaigns but retain clinical importance because they are used where disease severity, treatment failure, or inability to take oral medicine requires rapid and controlled intervention.
Topical
Topical products accounted for 14.35% of market revenue in 2025 and are projected to expand at the fastest route-level CAGR of 7.66%. Topical permethrin and ivermectin products are commonly used for scabies and lice, where localized delivery can reduce systemic exposure and support outpatient treatment.
Formulation research is exploring nanoparticle-enabled topical delivery to improve drug release and pharmacokinetic performance relative to conventional preparations. Commercial adoption will depend on whether these technologies can demonstrate meaningful clinical, stability, and manufacturing advantages over low-cost established topical therapies.
By Distribution Channel
Hospital Pharmacies
Hospital pharmacies held the largest distribution-channel share at 43.11% in 2025 and are forecast to grow at a 6.22% CAGR. They dispense treatments for severe malaria, visceral leishmaniasis, neurocysticercosis, and complicated strongyloidiasis, where inpatient management or specialist supervision is required. Centralized hospital purchasing also supports high-volume tenders for public-sector programs.
Retail Pharmacies
Retail pharmacies accounted for 31.67% of market revenue in 2025 and are projected to grow at a 7.78% CAGR. They provide accessible distribution for oral anthelmintics, antiprotozoals, and ectoparasiticides, particularly in areas where patients may seek treatment before reaching hospital services. Generic availability and local distribution coverage are critical competitive factors in this channel.
Online Pharmacies
Online pharmacies represented 25.22% of market revenue in 2025 and are projected to grow at the fastest channel CAGR of 8.02%. Digital dispensing is most relevant for repeat oral treatments, travel-medicine consultations, and patient access in markets with established e-prescribing and licensed delivery systems. The channel's growth does not eliminate the need for physical distribution, particularly for hospital-administered injectables and medicines used in public-health campaigns.
GMI Analyst View
Our assessment suggests that the market's fastest-growing revenue pools are not necessarily its highest-volume treatment pools. Anthelmintics remain the largest category because mass treatment programs require large volumes of low-cost oral medicines, whereas antiprotozoals grow faster because resistance, combination therapy, and more complex clinical indications raise the value captured per course of treatment.
The route and channel mix reinforces this distinction. Oral products hold 54.10% of revenue because they fit preventive programs and decentralized care, while topical products and online pharmacies grow faster from smaller bases as care becomes more consumer-accessible. Suppliers that compete only on molecule availability may be exposed to tender pressure; suppliers that can offer pediatric formats, reliable hospital supply, differentiated topical products, or digitally compatible dispensing models have more ways to protect value.
Antiparasitic Drugs Market Regional Analysis
North America
North America held the largest regional share at 36.77% in 2025 and is projected to grow at a 6.34% CAGR. The United States remains the principal market, increasing from USD 6.1 billion in 2022 to USD 6.8 billion in 2025. The region combines advanced diagnostics, high healthcare spending, established hospital infrastructure, and demand related to travel-associated and imported parasitic disease.
CDC surveillance documented increased imported malaria cases in several southern U.S. border jurisdictions during 2023. This epidemiological pattern supports demand for specialty diagnosis and treatment even where endemic transmission is limited. The region also benefits from mature generic-drug approval pathways and hospital procurement systems.
Europe
Europe accounted for USD 5.9 billion in 2025, representing 28.56% of the market, and is forecast to grow at a 7.33% CAGR. Demand is supported by specialist infectious-disease services, cross-border travel, migrant health needs, and structured surveillance for zoonotic and foodborne disease.
The European Union One Health Zoonoses Report provides coordinated surveillance of zoonotic threats, including several parasitic diseases. [5]European Centre for Disease Prevention and Control - European Union One Health 2024 Zoonoses Report, 2024 - ecdc.europa.eu Imported malaria remains relevant, with more than 34,000 cases recorded across European reporting countries between 2015 and 2019. These factors sustain demand for specialist therapies and diagnostic-linked prescribing.
Asia Pacific
Asia Pacific accounted for 23.22% of global revenue in 2025 and is projected to grow at the highest regional CAGR of 8.23%. The region combines large endemic populations, variable sanitation conditions, improving healthcare access, and substantial pharmaceutical manufacturing capacity. India is particularly important because national programs address malaria, lymphatic filariasis, visceral leishmaniasis, and helminthic disease.
China's WHO malaria-free certification illustrates how sustained surveillance and treatment can change the regional demand profile from malaria control toward other parasitic conditions and imported infections. [6]World Health Organization - China certified malaria-free, June 2021 - who.int India's lymphatic-filariasis elimination objective has also supported continued large-scale medicine distribution and albendazole demand.
Latin America
Latin America held a 6.10% share of the market in 2025 and is forecast to grow at a 6.0% CAGR. Brazil is the largest regional contributor because of its population, broad tropical geography, and public healthcare procurement capacity. Malaria, leishmaniasis, Chagas disease, and helminthic infections maintain a diversified demand base.
The region's commercial opportunity is influenced by public-sector procurement and access policies. Demand for more specialized therapies is concentrated in larger health systems and endemic subregions, while broader generic demand is distributed through retail and public-health channels.
Middle East and Africa
Middle East and Africa accounted for 5.35% of global revenue in 2025 and are projected to grow at a 5.67% CAGR. Sub-Saharan Africa carries a disproportionate burden of malaria and several neglected tropical diseases, yet market value is limited by constrained purchasing power and reliance on donor-supported procurement. WHO reported that 95% of malaria deaths in 2024 occurred in the African Region.
The region's lower revenue share relative to disease burden reflects procurement economics rather than limited therapeutic need. Donor programs, medicine donations, public tenders, and country registration processes shape commercial access. Gulf markets contribute more conventional commercial demand through hospital and private-clinic systems serving mobile and expatriate populations.
GMI Analyst View
We expect North America to retain market leadership through 2035 because its value base is supported by high-cost clinical care, advanced diagnostics, hospital use of specialized medicines, and established regulated distribution. Its 36.77% 2025 share should not be interpreted as a proxy for disease burden; rather, it reflects the value generated per treated case and the region's ability to support premium hospital and specialty-pharmacy channels.
Asia Pacific's 8.23% projected CAGR identifies the more consequential expansion opportunity. The region combines endemic demand with manufacturing depth and improving health-system coverage, but its revenue trajectory will depend on tender execution, affordability, and national treatment-program continuity. The strategic divide is therefore clear: North America favors regulatory capability and specialty access, while Asia Pacific rewards scalable manufacturing, portfolio breadth, and participation in public-health delivery systems.
Antiparasitic Drugs Market Share & Competitive Landscape
The market is moderately consolidated, with the five leading companies accounting for approximately 45% of global revenue in 2025. Competition is determined by portfolio coverage, manufacturing scale, registration capabilities, quality compliance, tender participation, and access to hospital, retail, and public-health channels.
AdvaCare Pharma
AdvaCare Pharma supplies antiparasitic products including albendazole, mebendazole, ivermectin, and praziquantel across multiple dosage forms. Its positioning is most relevant in cost-sensitive markets where tender participation, distributor relationships, and dependable generic supply determine access.
Ajanta Pharma
Ajanta Pharma has a meaningful presence in India, Asia Pacific, and African markets. Its antimalarial and anthelmintic portfolio supports participation in markets where branded generics and institutional purchasing operate alongside retail distribution.
Alkem Laboratories
Alkem Laboratories serves the antiparasitic market through broad generic and anti-infective capabilities. Its domestic Indian distribution network and export activity provide access to hospital, retail, and clinic-based demand.
Cadila Pharmaceuticals
Cadila Pharmaceuticals markets anti-infective and antiparasitic formulations for domestic and export markets. Its competitive position is linked to cost-effective manufacturing and participation in institutional and retail supply channels.
Cipla
Cipla is among the leading market participants and maintains a portfolio spanning anthelmintic, antiprotozoal, and ectoparasitic therapies. The company received U.S. FDA final approval for albendazole tablets through the abbreviated new drug application pathway, strengthening its access to the U.S. generic anthelmintic market.
Dr. Reddy's Laboratories
Dr. Reddy's Laboratories competes through international generic-drug registrations and manufacturing capacity. The company received U.S. FDA approval for hydroxychloroquine sulfate tablets for malaria treatment in July 2021, providing a regulated-market position in an antiplasmodial therapy.
GlaxoSmithKline
GlaxoSmithKline has a substantial position in anthelmintics through Zental and its long-standing albendazole donation program. In June 2022, the company reaffirmed commitments to donate albendazole for lymphatic-filariasis control and other neglected tropical disease programs. Its combination of donation activity, private-market sales, and institutional participation supports broad reach.
Intas Pharmaceuticals
Intas Pharmaceuticals supplies generic anti-infective and antiparasitic products for Indian and export markets. Its capabilities across oral and injectable dosage forms are relevant to hospital and retail demand.
Ipca Laboratories
Ipca Laboratories participates through antimalarial active pharmaceutical ingredient production and formulated antiparasitic products. Its portfolio includes albendazole products and antimalarial-related manufacturing capabilities, supporting institutional and commercial supply.
Mankind Pharma
Mankind Pharma markets antiparasitic products including albendazole-based combinations and ivermectin formulations. Its large domestic field network provides a distribution advantage in India's physician-led and retail pharmacy channels.
Novartis
Novartis maintains a major antiprotozoal position through Coartem and related malaria initiatives. Swissmedic approved Coartem Baby in July 2025 for newborns and young infants, with additional approvals anticipated in African countries through the Marketing Authorization for Global Health Products pathway. The company also reported positive Phase III KALUMA results for ganaplacide/lumefantrine in November 2025.
Sanofi
Sanofi is active in treatments for human African trypanosomiasis through fexinidazole. In December 2023, the EMA Committee for Medicinal Products for Human Use issued a positive scientific opinion for Fexinidazole Winthrop for acute *T. b. rhodesiense* sleeping sickness.
Teva Pharmaceuticals
Teva Pharmaceuticals competes through its global generic portfolio, established regulatory approvals, and distribution relationships across hospital and retail channels. Its broad manufacturing and commercial infrastructure supports availability of generic antiparasitic therapies in regulated and emerging markets.
Weefsel Pharma
Weefsel Pharma supplies generic anti-infective and antiparasitic medicines, primarily for India and selected emerging markets. The company contributes to affordable supply in retail and institutional channels.
Recent Industry Developments
Need a specific section of this report?
Purchase regional analysis, country-level analysis, company profiles, or any other segment-level insights separately
based on your research needs.
Frequently Asked Question(FAQ) :
Research methodology, data sources & validation process
This report draws on a structured research process built around direct industry conversations, proprietary modelling, and rigorous cross-validation and not just desk research.
Our 6-step research process
1. Research design & analyst oversight
At GMI, our research methodology is built on a foundation of human expertise, rigorous validation, and complete transparency. Every insight, trend analysis, and forecast in our reports is developed by experienced analysts who understand the nuances of your market.
Our approach integrates extensive primary research through direct engagement with industry participants and experts, complemented by comprehensive secondary research from verified global sources. We apply quantified impact analysis to deliver dependable forecasts, while maintaining complete traceability from original data sources to final insights.
2. Primary research
Primary research forms the backbone of our methodology, contributing nearly 80% to overall insights. It involves direct engagement with industry participants to ensure accuracy and depth in analysis. Our structured interview program covers regional and global markets, with inputs from C-suite executives, directors, and subject matter experts. These interactions provide strategic, operational, and technical perspectives, enabling well-rounded insights and reliable market forecasts.
3. Data mining & market analysis
Data mining is a key part of our research process, contributing nearly 20% to the overall methodology. It involves analysing market structure, identifying industry trends, and assessing macroeconomic factors through revenue share analysis of major players. Relevant data is collected from both paid and unpaid sources to build a reliable database. This information is then integrated to support primary research and market sizing, with validation from key stakeholders such as distributors, manufacturers, and associations.
4. Market sizing
Our market sizing is built on a bottom-up approach, starting with company revenue data gathered directly through primary interviews, alongside production volume figures from manufacturers and installation or deployment statistics. These inputs are then pieced together across regional markets to arrive at a global estimate that stays grounded in actual industry activity.
5. Forecast model & key assumptions
Every forecast includes explicit documentation of:
✓ Key growth drivers and their assumed impact
✓ Restraining factors and mitigation scenarios
✓ Regulatory assumptions and policy change risk
✓ Technology adoption curve parameter
✓ Macroeconomic assumptions (GDP growth, inflation, currency)
✓ Competitive dynamics and market entry/exit expectations
6. Validation & quality assurance
The final stages involve human validation, where domain experts manually review filtered data to identify nuances and contextual errors that automated systems might miss. This expert review adds a critical layer of quality assurance, ensuring data aligns with research objectives and domain-specific standards.
Our triple-layer validation process ensures maximum data reliability:
✓ Statistical Validation
✓ Expert Validation
✓ Market Reality Check
Trust & credibility
Verified data sources
Trade publications
Industry journals, trade publications, and specialized media.
Industry databases
Proprietary and third-party market databases
Regulatory filings
Government procurement records and policy documents
Academic research
University studies and specialist institution reports
Company reports
Annual reports, investor presentations, and filings
Expert interviews
C-suite, procurement leads, and technical specialists
GMI archive
13,000+ published studies across 20+ industry verticals
Trade data
Import/export volumes, HS codes, and customs records
Parameters studied & evaluated
Every data point in this report is validated through primary interviews, true bottom-up modelling, and rigorous cross-checks. Read about our research process →